Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Acute severe ulcerative colitis"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
A survey on the practices and patterns in the management of acute severe ulcerative colitis in India
Arshia Bhardwaj, Arshdeep Singh, Riya Sharma, Vandana Midha, Ajit Sood
Received April 21, 2025  Accepted August 18, 2025  Published online November 14, 2025  
DOI: https://doi.org/10.5217/ir.2025.00060    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The real-world management of acute severe ulcerative colitis (ASUC) varies considerably across regions and healthcare settings. This study aimed to evaluate current management practices for ASUC among gastroenterologists in India.
Methods
A structured, web-based survey covering 5 thematic domains (provider and institutional characteristics, clinical workload and initial management, diagnostic practices, infectious work-up, and strategies for rescue therapy) was disseminated via email. Responses were analyzed using descriptive statistics.
Results
A total of 228 responses were received from across India’s 5 geographic zones. The majority of respondents were affiliated with either corporate hospitals (n = 76, 33.3%) or teaching hospitals (n = 68, 29.8%). The majority (n = 135, 59.2%) reported managing up to 10 ASUC cases annually. The Truelove and Witts criteria were the most commonly used for diagnosis (n = 169, 74.1%). Nutritional assessment was performed by 89 respondents (39.0%). Biopsies for cytomegalovirus during index sigmoidoscopy were obtained by 75 (32.9%). Intravenous hydrocortisone was the preferred steroid (n = 188, 82.5%). Low molecular weight heparin for thromboprophylaxis was never prescribed by 62 respondents (27.2%). Oxford criteria were most frequently used to assess steroid response (n = 150, 65.8%). More than half of the respondents (n = 125, 54.8%) reported that fewer than 50% of patients accepted rescue therapy. Rescue therapy was initiated on or after day 5 by 153 respondents (67.1%). Early involvement of colorectal surgeons was reported by 66 (28.9%). A majority (n = 200, 87.7%) were associated with low-volume centers for ileal pouch-anal anastomosis, performing < 5 procedures per year.
Conclusions
This nationwide survey reveals considerable heterogeneity in ASUC management in India. Standardizing care through patient and healthcare provider education and context-specific guidelines is imperative.
  • 712 View
  • 117 Download
Close layer
Review
IBD
What to do when traditional rescue therapies fail in acute severe ulcerative colitis
Christopher F. D. Li Wai Suen, Matthew C. Choy, Peter De Cruz
Intest Res 2024;22(4):397-413.   Published online May 16, 2024
DOI: https://doi.org/10.5217/ir.2024.00003
AbstractAbstract PDFPubReaderePub
Acute severe ulcerative colitis (ASUC) is a medical emergency that affects approximately 25% of patients with ulcerative colitis at some point in time in their lives. Outcomes of ASUC are highly variable. Approximately 30% of patients do not respond to corticosteroids and up to 50% of patients do not respond to rescue therapy (infliximab or cyclosporin) and require emergency colectomy. Data are emerging on infliximab dosing strategies, use of cyclosporin as a bridge to slower acting biologic agents and Janus kinase inhibition as primary and sequential therapy. In this review, we outline contemporary approaches to clinical management of ASUC in the setting of failure to respond to traditional rescue therapies.

Citations

Citations to this article as recorded by  
  • Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC
    Christopher F.D. Li Wai Suen, Matthew C. Choy, Danny Con, Kaylene Cheng, Julie Nigro, Kerry Breheney, Kristy Boyd, Raquel Pena, Kathryn Burrell, Ourania Rosella, David Proud, Richard Brouwer, Alexandra Gorelik, Danny Liew, William R. Connell, Emily K. Wri
    Gastroenterology.2026; 170(1): 118.     CrossRef
  • Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
    Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha
    Intestinal Research.2026; 24(1): 27.     CrossRef
  • Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department
    Christopher F. D. Li Wai Suen, Shipraa Kaul, Ethan X. Z. Tan, Danny Con, Michelle Taylor, Joanne Wiid, Chris Hogan, Matthew C. Choy, Kumar Visvanathan, Peter De Cruz
    Digestive Diseases and Sciences.2026;[Epub]     CrossRef
  • Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis – Authors’ reply
    Christopher F D Li Wai Suen, Matthew C Choy, Danny Con, Peter De Cruz
    The Lancet Gastroenterology & Hepatology.2025; 10(1): 19.     CrossRef
  • Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review
    Javier P Gisbert, María Chaparro
    Journal of Crohn's and Colitis.2025;[Epub]     CrossRef
  • Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series
    Amirah Etchegaray, George Tambakis, Rina Kumar, Anthony Croft, Graham Radford-Smith, Gareth J. Walker
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
    Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
    Gut and Liver.2025; 19(3): 376.     CrossRef
  • Three Janus kinase inhibitors in ulcerative colitis: is upadacitinib taking the lead?
    Yoon Suk Jung
    Intestinal Research.2025; 23(4): 394.     CrossRef
  • Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice
    Javier P Gisbert, María Chaparro
    Inflammatory Bowel Diseases.2025;[Epub]     CrossRef
  • Recent Advances in the Management of Acute Severe Ulcerative Colitis
    Elaine Ong Ming San, Kassem Sharif, Konstantina Rosiou, Michael Rennie, Christian Philipp Selinger
    Journal of Clinical Medicine.2024; 13(23): 7446.     CrossRef
  • 11,616 View
  • 387 Download
  • 10 Web of Science
  • 10 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP